Member Info for GreggsStottie

Thanks Sneller, really appreciate the very low top up price last week. Onwards and upwards...back to £1+ we go.

You make some good points about the government wanting to keep control of testing. I agree as it opens up the possibility of people lying which is human nature...you can imagine it cant you!!..."yeah, I have no symptoms but I have paid for a concert, can you do a test for me so I can go?" Pepole are inherantly selfish or stupid or both.

Once MRHA approval comes wait for the target price...many multiples of todays price...I expect £3.00+ once news hits.

I agree with most of the comments on the board here, most sold because they dont understand why ODX is needed...but you need to know if the vaccine has worked and to check those that need a vaccine...on trial in 18 countries including India. Bring it on...

I can see capacity increasing to 5m in H2 2021....

GL all...

Isn't the margin more like 75%...?

Thanks for your analysis...bring it on!

Well, based on what we know (i.e. 2.5m tests a week) that is just the 1st target...!

I cant ever fathom charts...a dark art...sentiment will play a big part in the rerate, plus the end of L&G selling.....

Part of the reason we have fallen is an institution selling, then the vaccine news.

I can see this getting back to 70's next week...skysthelimit when mrha approval hits the red dot.

If we can ramp up production from 100000 to 2.5m, I presume we can double that again.

Perhaps the Littleport (Ely site) could be expanded...its in the middle of nowhere on google maps.

A great day today and the start of our rerate back to where if should be. MRHA approval is the next big news...unless of course a predator wants to buy the company....

With so much good news on the horison a takeover is not beyond the realm of possibility.

Manage to grt my average down to 52p today so very pleased to be in a position to do that. Whilst I agree sentiment has pushed this down, the spring back will push us well above £1 when MRHA approval comes.

We will have the capacity to do 2.5m tests a week in 2021 which will bring in serious wonga. But, the government needs to get into gear and get the approvals completed. Producing at scale takes time, and we have a worldwide audience who needs our capacity. Do the uk govt want to miss out on this capacity, NO. So the approval will come...probably in December in readiness for the ramp up in capacity from January through to April.

Until then, I presume we are storing tests on the basis of large orders coming. You dont ramp up production capacity to 2 5m tests on a whim...you make sure the pipeline is there first and then produce in readiness.

All the best people...

January is perfect timing for the P3 trials to be completed...emergency use here we come!!!

Takenorisk...its in the Numis report...£300m a month.

Cheers meelie..£85 a share...a bit less with dilution now but lordy lord that would be dream boat territory.

I think whatever happens I will off load a chunk of shares if and when we get in the teens £'s. Then let the rest ride.

10 times the current sp is not insurmountable in H1 2021 assuming the p3 trials go to plan. I can see RM getting the 100000 courses up to 2/3/4/500000 courses a month to drive value in 2021. This drug has worldwide need and governments will stockpile.

Bring it on.

We will also have the cash to develop copd trials anx possibly pay a dividend in 2022...

Would someone be kind enough to post the bones of the Numis broker research?

Thank you in advance...

I recall seeing a broker note or a message on here stating £50 a share potential...assume that is diluted to c £40 now.

Does anyone know where this came from?

Cheers in advance...

Thanks redhotcilli...saved me a job explaining that.

Its easy to see how we coukd get to £25-£40 a share if production was accelerated....and partnerinv across the globe. Ker-ching.....

I have reread the Finncap broker note this afternoon and it fills me with positivity.....someone asked for a link to the note, however you need to open an account on finncap for free to get full access.

Risked target sp £4.20...
Covid 19 worth 3.36 based on assumptions of $1.25bn sales, 70% chance of getting to mkt, 30% return on sales and 10% discounted rate. (However sales are likely to be $3.6bn on 100000 doses a month.
Post phase III value £6.66 based on 30% margin, however its c.£12-£13 based on 60%-65%!!!!!!!!!!!!! Stockpiling could drive sales much higher and drive the sp...!!!!!!!!!!

We also have COPD...which is valued at 52p currently (Risked on £1bn sales, 30% chance of getting to market, 15% margin...plus discount rate of 10%).

We also own 17% of Loxl2 which is valued at 9p...this one is a while off but useful info.

Covid 19 £3.36 to £13.00 but could be higher.
COPD 52p but is heavily risked and could be massive.
LOXl2 9p, but again has potrntial yo be much higher once PXL get a partner for this.

Sll in all we are looking for a sp of between £3.97 and £13.61, however deprndant on capacity, stockpiling, demamd etc could be much larger.

Phase III results out in March 2021...its gojng to be an interesting 4 months...emergrncg use could pull this forward and propel the sp north in q1.

Oh, and SNG have c. £17m cash from the recent placing to negotiatd with a large pharma. Bring it on!

GL all...

Same here, 95.2%. Very pleased.

Onwards and upwards from here on in.

I did also take a chunk af £1.66 so great to see thd sp lift today. We need the pieces of the jigsaw to come together now.

Peer review
Commencement of stage 3 trials
Completion of home trials, perhaps some data.
20 rns's ref placing shares!

Its going to be some journey over the next year!

My std offer shares have now been added in II. I am assuming the extra ones will be added in due course.

Some have said they are getting all their extra ones, however I am not sure if this is the case or not.

I am sure we will find out very soon.

...when they are in your account. Lol

The Resolutions are contained in the Notice of General Meeting at the end of the Circular. Conditional Admission is expected to occur at 8.00 a.m. on 4 November 2020 or such later time and/or date as finnCap, Numis and the Company may agree, not being later than 8.30 a.m. on 4 November 2020

By 8.30?